BiotechTube

INTERCEPT Platelets

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
15
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chikungunya Virus

Conditions

Chikungunya Virus, Dengue Virus

Trial Timeline

Mar 1, 2015 → May 1, 2016

NCT ID
NCT02305732

About INTERCEPT Platelets

INTERCEPT Platelets is a pre-clinical stage product being developed by Cerus for Chikungunya Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT02305732. Target conditions include Chikungunya Virus, Dengue Virus.

Hype Score Breakdown

Clinical
5
Activity
2
Company
2
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT02305732Pre-clinicalCompleted

Competing Products

20 competing products in Chikungunya Virus

See all competitors
ProductCompanyStageHype Score
CHIKV VLP/unadjuvanted + CHIKV VLP/adjuvanted + PlaceboBavarian NordicPhase 2
49
ChikungunyaBavarian NordicPhase 2
49
CHIKV VLP vaccine booster + Placebo boosterBavarian NordicPhase 3
74
CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3
74
CHIKV VLP, adjuvantedBavarian NordicPhase 2
49
CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3
74
CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3
74
CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3
74
Live-attenuated CHIKV vaccine VLA1553Valneva SEPre-clinical
18
VLA1553Valneva SEPhase 3
72
Live-attenuated CHIKV vaccine VLA1553Valneva SEPre-clinical
18
Biological Vaccine VLA1553Valneva SEPhase 3
72
VLA1553 full dose + VLA1553 half dose + ControlValneva SEPhase 2
47
Active + PlaceboValneva SEPhase 3
72
Live-attenuated CHIKV vaccine VLA1553 + Vaccine(s) approved for use during pregnancy by the MoHValneva SEPre-clinical
18
VLA1553Valneva SEPhase 3
72
VLA1553 + ControlValneva SEPhase 3
72
VLA1553 + PlaceboValneva SEPhase 3
72
VLA1553Valneva SEPhase 1
28
Live-attenuated CHIKV vaccine VLA1553Valneva SEPre-clinical
18

Other Products from Cerus

Traditional Cryoprecipitate + Pathogen-Reduced CryoprecipitateApproved
77
Pathogen-Reduced Plasma + Crystalloid SolutionsApproved
77
S-303 Treated Red Blood Cells (RBCs) + Conventional, untreated Red Blood CellsPhase 3
69
S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - ControlPhase 3
69
Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets. + Autologous apheresis Conventional untreated Platelet ComponentsPhase 2
44